Evgen Pharma plc (LON:EVG) – BUY*: Services agreement with APTrans
Market Cap: £14m; Current Price: 19.5p; Target Price: 97p
Services agreement with drug development consortium APTrans
Evgen announced the signing of a services agreement with APTrans to support the ongoing development of lead product, SFX-01.
APTrans is a consortium of drug development companies based in the Biohub at Alderley Park (Cheshire)—the former AstraZeneca research campus.
APTrans works with clients to help them transform molecules into medicines.
NORTHLAND CAPITAL PARTNERS VIEW: Evgen’s agreement with APTrans provides a flexible way to access specialist technical expertise to complement the group’s existing drug development capabilities. APTrans is an AstraZeneca spinout and is located at the Biohub where Evgen also has a presence.
Ascent Resources (LON:AST) – CORP: Fundraise
Market Cap: £30m; Current Price: 2.2p
Raises £2.9m
Ascent Resources has raised £2.9m through the issue of 161,500,000 shares at a price of 1.85p per share.
Following the placing the Company will have 1,510,578,713 shares in issue.
NORTHLAND CAPITAL PARTNERS VIEW: Ascent Resources will use these funds to continue to develop the Petišovci Gas Field, including the recompletion of Pg-11A and general working capital.